United Therapeutics (UTHR) Tops Q1 EPS by 7c, Miss on Revenues
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $497.97 +2.12%
Revenue Growth %: -1.2%
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -1.2%
Financial Fact:
Net income per diluted common share (in dollars per share): 3.5
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $3.61, $0.07 better than the analyst estimate of $3.54. Revenue for the quarter came in at $370.5 million versus the consensus estimate of $398.18 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Casey's General Stores (CASY) Tops Q1 EPS by 69c
- ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
- BMO Capital Starts Lululemon (LULU) at Underperform
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
